De Vecchis R, et al. - The combination drug sacubitril/valsartan was reported to be superior to enalapril in reducing all-cause death, cardiovascular mortality, and heart failure (HF) hospitalizations in patients with cardiac insufficiency and reduced left ventricular ejection fraction (HFREF) with New York Heart Association (NYHA) class II–IV. In this retrospective cohort study, it was shown that sacubitril/valsartan provided strong protection against all-cause death and HF hospitalizations at 6 months without any significant side effects in HFREF patients with NYHA class II–III HF who received sacubitril/valsartan in addition to a beta-blocker and mineral receptor antagonist (MRA), compared with a control group of HFREF patients with comparable clinical features treated with conventional therapy (ACE inhibitor or angiotensin II receptor blocker added to a beta-blocker plus an MRA).